Integral Molecular announces the launch of SARS-CoV-2 Reporter Virus Particles (RVPs) to test patients for the presence of neutralizing antibodies, determine the effectiveness of vaccines, and measure the efficacy of drugs to enable expedited testing of new vaccines and therapeutics. Read more...
The first U.S. patients have been dosed in a clinical trial testing whether four experimental mRNA vaccine candidates can prevent infection with the virus that causes COVID-19 disease. Read more...
AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. Read more...